{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:16:15Z","timestamp":1784938575089,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002714","name":"Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110883","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:07:57Z","timestamp":1744733277000},"page":"110883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)"],"prefix":"10.1016","volume":"208","author":[{"given":"Simon K.B.","family":"Spohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"B\u00fcrkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gainey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Kamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolina","family":"Toncheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sprave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kirste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"Sigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Adebahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Zschaeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirus","family":"Ghadjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Baltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110883_b0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/pros.24184","article-title":"Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores","volume":"81","author":"Wenzel","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.radonc.2025.110883_b0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110883_b0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0020","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0025","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.110883_b0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0040","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[(68)Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard \u2013 implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110883_b0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.09.003","article-title":"European association of nuclear medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer","volume":"85","author":"Oprea-Lager","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110883_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109774","article-title":"Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer","volume":"188","author":"Holzschuh","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0060","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2967\/jnumed.120.254623","article-title":"Intraprostatic tumor segmentation on PSMA PET images in patients with primary prostate cancer with a convolutional neural network","volume":"62","author":"Kostyszyn","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2025.110883_b0065","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1038\/s41598-021-85028-5","article-title":"The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer","volume":"11","author":"Zamboglou","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110883_b0070","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s00259-020-04827-6","article-title":"Intraindividual comparison between (68)Ga-PSMA-PET\/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients","volume":"47","author":"Spohn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2025.110883_b0075","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s00259-014-2861-0","article-title":"11C-Choline PET\/pathology image coregistration in primary localized prostate cancer","volume":"41","author":"Grosu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2025.110883_b0080","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.15344","article-title":"(68)Ga-HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.radonc.2025.110883_b0085","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110883_b0090","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.7150\/thno.32376","article-title":"Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate-and high-risk prostate cancer\u2013a comparison study with histology reference","volume":"9","author":"Zamboglou","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.radonc.2025.110883_b0095","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.27303.1","article-title":"PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study [version 1; peer review: 1 approved, 1 approved with reservations]","volume":"9","author":"Rogasch","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.radonc.2025.110883_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0105","doi-asserted-by":"crossref","unstructured":"Tselis N, Baltas D, Zamboglou N. Prostate: high-dose rate brachytherapy in the treatment of clinically organ-confined prostate cancer. In: Montemaggi P, Trombetta M, Brady LW, editors. Brachytherapy: An International Perspective. Cham: Springer International Publishing; 2016. p. 319-43.","DOI":"10.1007\/978-3-319-26791-3_19"},{"key":"10.1016\/j.radonc.2025.110883_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600690","article-title":"Comparison of manual and semi-automatic [(18)F]PSMA-1007 PET Based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference","volume":"10","author":"Spohn","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.radonc.2019.07.002","article-title":"Validation of different PSMA-PET\/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference","volume":"141","author":"Zamboglou","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0120","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110883_b0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00066-011-0015-x","article-title":"The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"188","author":"Hodapp","year":"2012","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft[et al]"},{"key":"10.1016\/j.radonc.2025.110883_b0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0135","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110883_b0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110883_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0155","doi-asserted-by":"crossref","unstructured":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92-8.","DOI":"10.1016\/j.radonc.2020.03.015"},{"key":"10.1016\/j.radonc.2025.110883_b0160","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","article-title":"Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation","volume":"106","author":"Wilkins","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110883_b0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2016.02.004","article-title":"Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial","volume":"119","author":"Gomez-Iturriaga","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0170","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00384-015-2289-4","article-title":"Chronic radiation proctitis: tricks to prevent and treat","volume":"30","author":"Vanneste","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.radonc.2025.110883_b0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"The fraction size sensitivity of late genitourinary toxicity: analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110883_b0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose\u2013effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0185","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2021.06.033","article-title":"Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"162","author":"Groen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1371384","article-title":"Predictors of radiation-induced late rectal toxicity in prostate cancer treatment: a volumetric and dosimetric analysis","volume":"14","author":"Spohn","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110883_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110883_b0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12885-022-09434-2","article-title":"Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients","volume":"22","author":"Spohn","year":"2022","journal-title":"BMC Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:57:05Z","timestamp":1753775825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025001781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"alternative-id":["S0167814025001781"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110883","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110883"}}